Regular Articles
Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage

https://doi.org/10.2353/ajpath.2010.090276Get rights and content
Under an Elsevier user license
open archive

Ischemia-reperfusion injury is the major cause of delayed graft function in transplanted kidneys, an early event significantly affecting long-term graft function and survival. Several studies in rodents suggest that the alternative pathway of the complement system plays a pivotal role in renal ischemia-reperfusion injury. However, limited information is currently available from humans and larger animals. Here we demonstrated that 30 minutes of ischemia resulted in the induction of C4d/C1q, C4d/MLB, and MBL/MASP-2 deposits in a swine model of ischemia-reperfusion injury. The infusion of C1-inhibitor led to a significant reduction in peritubular capillary and glomerular C4d and C5b-9 deposition. Moreover, complement-inhibiting treatment significantly reduced the numbers of infiltrating CD163+, SWC3a+, CD4a+, and CD8a+ cells. C1-inhibitor administration led to significant inhibition of tubular damage and tubular epithelial cells apoptosis. Interestingly, we report that focal C4d-deposition colocalizes with C1q and MBL at the peritubular and glomerular capillary levels also in patients with delayed graft function. In conclusion, we demonstrated the activation and a pathogenic role of classical and lectin pathways of complement in a swine model of ischemia-reperfusion−induced renal damage. Therefore, inhibition of these two pathways might represent a novel therapeutic approach in the prevention of delayed graft function in kidney transplant recipients.

Cited by (0)

Supported by University of Bari and Regione Puglia (PhD in Biotechnology applied to Organ and Tissue Transplantation, R.M. and C.D.) and an unrestricted research grant from Pharming Group NV, Leiden, The Netherlands.

G.C. and R.M. equally contributed to the present study.

Pharming Group NV has a financial interest in the use of recombinant human C1 inhibitor (rhC1NH) in preventing delayed graft function after solid organ transplantation.